JUN 06, 2019 10:45 AM PDT

Drug Regimen Improves Clinical Outcomes for Kidney Transplant Patients

WRITTEN BY: Nouran Amin

Recent preliminary clinical trial results indicate the immunosuppressive drug belatacept can safely and effectively treat kidney transplant patients without adverse long-term side effects of traditional immunosuppressive regimens. Belatacept was approved by the U.S. Food and Drug Administration in 2011 for the prevention of immune rejection in kidney transplant patients and is the modified form of another drug called abatacept which treats rheumatoid arthritis.

The clinical trial is known as the Belatacept Early Steroid Withdrawal Trial (BEST) represented a significant step forward in enhancing the quality of life for postoperative patients receiving kidney transplantation.

"In the BEST trial, we tried to achieve something that hadn't been done in transplantation: to eliminate the use of corticosteroids very early after surgery and at the same time avoid the toxicities associated with the cornerstone immunosuppressive medications that had been used for four decades," said principal investigator E. Steve Woodle, MD, William A. Altemeier Professor in Research Surgery at the UC College of Medicine and director of Solid Organ Transplantation for UC Health."We wanted to reduce the side effects and toxicities of these medications and make it easier for patients to tolerate their anti-rejection drugs, while achieving rejection rates that are reasonable, this work solved a vexing 40-year-old problem and represents a major step forward in the field of transplantation."

Findings of the two-year study did not utilize the long-term use of prednisone (a corticosteroid) or tacrolimus (a calcineurin inhibitor).

"The primary problem that has prevented elimination of corticosteroids and calcineurin inhibitors to date has been excessive rejection rates," stated Rita Alloway, PharmD, research professor of nephrology at the UC College of Medicine and director of Transplant Clinical Research at UC Health. "The BEST Trial demonstrates that rejection risk with the new belatacept-based regimens was increased somewhat, and the reduced side effects and long-term cardiovascular risk reduction are major potential advantages of these regimens for the future."

Learn more about rejection following transplantation:

The standard care of treatment for patients who receive a kidney transplant is a post-surgery regimen involving corticosteroid and calcineurin inhibitor (CNI) immunosuppressants. These drugs have long been known to help organ transplant patients survive but can result in kidney toxicity or cardiovascular damage.

"This CNI- and steroid-free [immunosuppressive] protocol is a promising step forward in minimizing toxicities and improving renal allograft function," noted the author of the study. "Longer-term observations will need to be continued."

Source: University of Cincinnati

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
FEB 25, 2021
Drug Discovery & Development
Future COVID-19 Targets Rapidly Identified with Computer Simulations
FEB 25, 2021
Future COVID-19 Targets Rapidly Identified with Computer Simulations
A recent mechanism as detailed in the novel SARS-CoV2 that causes COVID-19 could help scientists find new therapeutics. ...
MAR 06, 2021
Genetics & Genomics
Green Tea Extract Can Affect Facial Development in Kids With Down Syndrome
MAR 06, 2021
Green Tea Extract Can Affect Facial Development in Kids With Down Syndrome
Individuals with Down syndrome often have certain facial features. New research has suggested that green tea supplements ...
MAR 30, 2021
Drug Discovery & Development
Common Alzheimer's Drugs Reduce Mortality Rate and Cognitive Decline
MAR 30, 2021
Common Alzheimer's Drugs Reduce Mortality Rate and Cognitive Decline
Researchers from the Karolinska Institute and Umea University in Sweden have found that a commonly recommended group of ...
APR 03, 2021
Drug Discovery & Development
Why Are Some Cancer Therapeutics Ineffective?
APR 03, 2021
Why Are Some Cancer Therapeutics Ineffective?
Why don’t some cancer therapeutics not work in humans when they were successful in mice? The answer to this questi ...
MAY 04, 2021
Health & Medicine
Micro-dosing Inhaler Breakthrough for Medical Cannabis
MAY 04, 2021
Micro-dosing Inhaler Breakthrough for Medical Cannabis
In a leap that will eliminate the risks of vaping or smoking, Canada has just approved an Israeli-made inhaler that is a ...
MAY 06, 2021
Drug Discovery & Development
Are Hallucinations Necessary for Psychedelics to Treat Depression?
MAY 06, 2021
Are Hallucinations Necessary for Psychedelics to Treat Depression?
Many who work with psychedelics say that hallucinations, or psychedelic experiences, are an integral part of psychedelic ...
Loading Comments...